Resistance Mechanisms and Sequential Treatment Strategies Following First-Line Lorlatinib in ALK-Positive NSCLC
Clinical trial NCT06904547 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06904547
- Sponsor
- Shanghai Chest Hospital
- Status
- NOT_YET_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2025-04-20
- Primary completion
- 2029-06-30
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.